At a glance
- Originator Otsuka Pharmaceutical
- Class Antibacterials; Imidazoles; Inorganic sulfur compounds; Quinolones; Small molecules
- Mechanism of Action 12-lipoxygenase inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 02 Oct 2001 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 27 Sep 1999 New profile
- 27 Sep 1999 Preclinical development for Thrombosis in Japan (Unknown route)